PAVmed(PAVM.US)

Last Updated 19:00:00 ET
longbridge loading

Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16

Tip Ranks·
US
PAVM
-6.25%
US
XHE
+1.64%
US
IHI
+1.07%
Tip Ranks·
US
PAVM
-6.25%
US
XHE
+1.64%
US
IHI
+1.07%

PAVmed Q1 2026 Earnings Call Transcript

benzinga_article·
US
PAVM
-6.25%
US
LUCD
+7.18%
US
IHI
+1.07%
benzinga_article·
US
PAVM
-6.25%
US
LUCD
+7.18%
US
IHI
+1.07%

PAVmed Reports Q1 2026 Results and Business Update

Tip Ranks·
US
PAVM
-6.25%
US
XHE
+1.64%
US
IHI
+1.07%
Tip Ranks·
US
PAVM
-6.25%
US
XHE
+1.64%
US
IHI
+1.07%

PAVmed | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22 K

Earnings Watch·
US
PAVM
-6.25%
Earnings Watch·
US
PAVM
-6.25%

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga_article·
US
AVTX
+0.77%
US
APUS
-1.76%
US
TMDX
+5.18%
benzinga_article·
US
AVTX
+0.77%
US
APUS
-1.76%
US
TMDX
+5.18%

PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026 | LUCD Stock News

StockTitan·
US
PAVM
-6.25%
US
LUCD
+7.18%
StockTitan·
US
PAVM
-6.25%
US
LUCD
+7.18%

Lishan Aklog Discloses Investment at PAVmed Inc. with 5.1% Stake

TradingView·
US
XHE
+1.64%
US
PAVM
-6.25%
US
IHI
+1.07%
TradingView·
US
XHE
+1.64%
US
PAVM
-6.25%
US
IHI
+1.07%
© 2026 Longbridge｜Disclaimer